QUECTEL-WIRELESS
20.6.2022 14:32:11 CEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announced the release of its LC76G module, a single-band compact GNSS module featuring fast and accurate location performance as well as ultra-low power consumption. The LC76G has already entered mass production with sufficient supply to meet the needs of the global positioning market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220620005121/en/
Based on the Airoha AG3352 platform, the LC76G can concurrently receive and process signals from all constellations (GPS, GLONASS, BeiDou, Galileo and QZSS), which in combination with the support of SBAS greatly increases the number of visible satellites and enhances positioning accuracy. The LC76G module can receive signals from up to 47 satellites and achieve 1.5m (CEP50 open-sky) positioning accuracy representing a 40% improvement over previous generations of devices.
Available in a cost-optimized version as well as a low-power version, the LC76G low-power version consumes less than 9mA @3V with all 4 constellations enabled allowing for a 72% reduction in power required than previously possible.
This makes the LC76G extremely attractive for battery operated devices such as wearable personal trackers, wildlife and livestock tracking, Toll tags, portable container trackers as well as a host of traditional markets such as Shared Mobility and low-cost asset trackers.
Featuring an internal SAW filter and integrated LNA, the LC76G can be connected directly to a passive patch antenna and provides filtering against unwanted interference ensuring excellent performance even while driving through dense urban canyons.
Integrated AGNSS technology EPO™, is supported on the LC76G module and reduces the time to first fix (TTFF) with a hot start taking less than 1 second, a warm start within 2 seconds, while the cold start can obtain accurate tracking fixes within 15 seconds. The faster GNSS fixes make it possible to use accurate positioning and navigation services anytime and anywhere with a smaller power budget than previously possible.
While EPO requires manual download of predicted orbits, the LC76G also supports EASY™ (Embedded Assist System) where predicted orbit information is collected directly from the Satellites and provides for up to 3 days of accelerated fixes.
Both EPO and Easy™ are available for each constellation allowing for faster TTFF and reduced dependency on any particular constellation.
Featuring an LCC form factor and an ultra-compact size of 10.1mm × 9.7mm ×2.4mm, the footprint of the LC76G is compatible with other industry solutions as well as Quectel’s legacy L76 and L76-LB modules, allowing for a smooth migration of existing designs to the latest low power GNSS technology.
In addition, Quectel offers a wide range of off-the-shelf and customized high-performance antennas which boost wireless connectivity significantly. Quectel’s LC76G can be combined with a selection of GNSS L1 antennas to enable various positioning requirements. Customized connector type and cable length as well as comprehensive antenna design and test support are also available to facilitate customer product development.
The LC76G will be on display at Embedded World Nuremberg on Booth No 171, Hall 5, June 21- 23 2022.
About Quectel:
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS and WiFi/BT modules, antennas and IoT connectivity. Listed on the Shanghai Stock Exchange (603236.SS), our international leadership is devoted to advancing IoT across the globe.
For more information: www.Quectel.com , LinkedIn , Facebook , and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220620005121/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom